Fingerprint
Dive into the research topics of 'Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically